12-15歲年齡組，沒有單獨做。5-11歲做了，還沒看到結果

5-11 歲

https://clinicaltrials.gov/ct2/show/NCT04816643

，

 

Phase 1 is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-μg dose in 12- to 15-year-olds in the C4591001 study.

The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group.

 

 

12-15歲，與成年組混在一起

https://clinicaltrials.gov/ct2/show/NCT04368728

在決定劑量的一期臨試中，沒有包括18歲以下的。12-15歲組，從二期開始加入。這就是為啥俺說廠家“偷工”。

• In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).